PL4153136T3 - Osmotyczne postacie dawkowania zawierające deutetrabenazynę i sposoby ich stosowania - Google Patents
Osmotyczne postacie dawkowania zawierające deutetrabenazynę i sposoby ich stosowaniaInfo
- Publication number
- PL4153136T3 PL4153136T3 PL21737870.2T PL21737870T PL4153136T3 PL 4153136 T3 PL4153136 T3 PL 4153136T3 PL 21737870 T PL21737870 T PL 21737870T PL 4153136 T3 PL4153136 T3 PL 4153136T3
- Authority
- PL
- Poland
- Prior art keywords
- deutetrabenazine
- methods
- dosage forms
- osmotic dosage
- osmotic
- Prior art date
Links
- MKJIEFSOBYUXJB-VFJJUKLQSA-N (3r,11br)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one Chemical compound C1CN2C[C@@H](CC(C)C)C(=O)C[C@@H]2C2=C1C=C(OC([2H])([2H])[2H])C(OC([2H])([2H])[2H])=C2 MKJIEFSOBYUXJB-VFJJUKLQSA-N 0.000 title 1
- 229950005031 deutetrabenazine Drugs 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
- 230000003204 osmotic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063037369P | 2020-06-10 | 2020-06-10 | |
| US202063037953P | 2020-06-11 | 2020-06-11 | |
| US202063044451P | 2020-06-26 | 2020-06-26 | |
| PCT/US2021/036778 WO2021252741A1 (en) | 2020-06-10 | 2021-06-10 | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4153136T3 true PL4153136T3 (pl) | 2024-06-24 |
Family
ID=78826343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21737870.2T PL4153136T3 (pl) | 2020-06-10 | 2021-06-10 | Osmotyczne postacie dawkowania zawierające deutetrabenazynę i sposoby ich stosowania |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11311488B2 (pl) |
| EP (2) | EP4364738A3 (pl) |
| JP (2) | JP7419571B2 (pl) |
| KR (2) | KR102638424B1 (pl) |
| CN (1) | CN115916154A (pl) |
| AU (3) | AU2021288087B2 (pl) |
| BR (1) | BR112022025185B1 (pl) |
| CA (1) | CA3186425A1 (pl) |
| CL (1) | CL2022003512A1 (pl) |
| DK (1) | DK4153136T3 (pl) |
| ES (1) | ES2975960T3 (pl) |
| FI (1) | FI4153136T3 (pl) |
| HR (1) | HRP20240303T1 (pl) |
| HU (1) | HUE065723T2 (pl) |
| IL (1) | IL298629A (pl) |
| LT (1) | LT4153136T (pl) |
| MX (1) | MX2022015742A (pl) |
| PE (1) | PE20230852A1 (pl) |
| PL (1) | PL4153136T3 (pl) |
| PT (1) | PT4153136T (pl) |
| RS (1) | RS65328B1 (pl) |
| SI (1) | SI4153136T1 (pl) |
| SM (1) | SMT202400118T1 (pl) |
| TW (1) | TW202214246A (pl) |
| WO (1) | WO2021252741A1 (pl) |
| ZA (1) | ZA202213478B (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3257711A1 (en) * | 2022-06-08 | 2023-12-14 | Auspex Pharmaceuticals, Inc. | Osmotic dosage forms containing deutetrabenazine and their methods of use |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3173876A (en) | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
| US3276586A (en) | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
| US3546142A (en) | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
| US3541006A (en) | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
| US3541005A (en) | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4200098A (en) | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
| US5082668A (en) | 1983-05-11 | 1992-01-21 | Alza Corporation | Controlled-release system with constant pushing source |
| US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| US20030161882A1 (en) | 2002-02-01 | 2003-08-28 | Waterman Kenneth C. | Osmotic delivery system |
| WO2007019393A2 (en) | 2005-08-04 | 2007-02-15 | Alza Corporation | Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties |
| US20120208773A1 (en) * | 2008-08-12 | 2012-08-16 | Valeant International (Barbados) Srl | Pharmaceutical compositions with tetrabenazine |
| ES2896678T3 (es) | 2008-09-18 | 2022-02-25 | Auspex Pharmaceuticals Inc | Derivados deuterados de benzoquinolina como inhibidores del transportador de monoamina vesicular 2 |
| JP2013501810A (ja) | 2009-08-12 | 2013-01-17 | ヴァリーント インターナショナル（バルバドス）エスアールエル | 医薬組成物 |
| CA2883641C (en) | 2012-09-18 | 2021-09-14 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| HRP20221106T1 (hr) * | 2015-03-06 | 2022-11-25 | Auspex Pharmaceuticals, Inc. | Postupci liječenja abnormalnih nevoljnih poremećaja pokreta |
| US10479787B2 (en) * | 2016-04-22 | 2019-11-19 | Lupin Limited | Process for preparation of tetrabenazine and deutetrabenazine |
| US20170312226A1 (en) * | 2016-04-28 | 2017-11-02 | Ascent Pharmaceuticals, Inc. | Pharmaceutical dosage forms |
| CN110709398A (zh) * | 2017-03-15 | 2020-01-17 | 奥斯佩克斯医药公司 | 氘代丁苯那嗪的类似物、其制备方法及用途 |
| US20190099377A1 (en) * | 2017-10-02 | 2019-04-04 | Powder Pharma Coating Inc. | Method for dry powder coating osmotic drug delivery system |
| JP7195345B2 (ja) * | 2018-03-05 | 2022-12-23 | アムニール コンプレックス プロダクツ リサーチ エルエルシー | 薬物の時間放出のためのプログラム可能な医薬組成物 |
| KR20210044817A (ko) * | 2018-08-15 | 2021-04-23 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
-
2021
- 2021-06-10 MX MX2022015742A patent/MX2022015742A/es unknown
- 2021-06-10 CN CN202180042147.5A patent/CN115916154A/zh active Pending
- 2021-06-10 HU HUE21737870A patent/HUE065723T2/hu unknown
- 2021-06-10 IL IL298629A patent/IL298629A/en unknown
- 2021-06-10 KR KR1020237000961A patent/KR102638424B1/ko active Active
- 2021-06-10 HR HRP20240303TT patent/HRP20240303T1/hr unknown
- 2021-06-10 PT PT217378702T patent/PT4153136T/pt unknown
- 2021-06-10 FI FIEP21737870.2T patent/FI4153136T3/fi active
- 2021-06-10 LT LTEPPCT/US2021/036778T patent/LT4153136T/lt unknown
- 2021-06-10 ES ES21737870T patent/ES2975960T3/es active Active
- 2021-06-10 DK DK21737870.2T patent/DK4153136T3/da active
- 2021-06-10 WO PCT/US2021/036778 patent/WO2021252741A1/en not_active Ceased
- 2021-06-10 AU AU2021288087A patent/AU2021288087B2/en active Active
- 2021-06-10 CA CA3186425A patent/CA3186425A1/en active Pending
- 2021-06-10 SM SM20240118T patent/SMT202400118T1/it unknown
- 2021-06-10 US US17/344,271 patent/US11311488B2/en active Active
- 2021-06-10 TW TW110121253A patent/TW202214246A/zh unknown
- 2021-06-10 PE PE2022002886A patent/PE20230852A1/es unknown
- 2021-06-10 PL PL21737870.2T patent/PL4153136T3/pl unknown
- 2021-06-10 JP JP2022576176A patent/JP7419571B2/ja active Active
- 2021-06-10 KR KR1020247005191A patent/KR20240025706A/ko active Pending
- 2021-06-10 BR BR112022025185-8A patent/BR112022025185B1/pt active IP Right Grant
- 2021-06-10 RS RS20240332A patent/RS65328B1/sr unknown
- 2021-06-10 EP EP23219522.2A patent/EP4364738A3/en active Pending
- 2021-06-10 EP EP21737870.2A patent/EP4153136B1/en active Active
- 2021-06-10 SI SI202130123T patent/SI4153136T1/sl unknown
-
2022
- 2022-03-01 US US17/683,732 patent/US20230022862A1/en not_active Abandoned
- 2022-12-09 CL CL2022003512A patent/CL2022003512A1/es unknown
- 2022-12-13 ZA ZA2022/13478A patent/ZA202213478B/en unknown
-
2023
- 2023-06-27 AU AU2023204103A patent/AU2023204103B2/en active Active
-
2024
- 2024-01-10 JP JP2024001864A patent/JP7769731B2/ja active Active
- 2024-03-19 US US18/609,809 patent/US20240307313A1/en active Pending
-
2025
- 2025-07-15 AU AU2025205457A patent/AU2025205457A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281082A (en) | Preparations of CXCR4 inhibitors and methods of preparation and use | |
| SG11202107614PA (en) | Pcsk9 inhibitors and methods of use thereof | |
| SG11202107615TA (en) | Pcsk9 inhibitors and methods of use thereof | |
| IL287751A (en) | kcnt1 inhibitors and methods of use | |
| IL287768A (en) | kcnt1 inhibitors and methods of use | |
| IL286248A (en) | Tyk2 inhibitors and uses thereof | |
| IL292810A (en) | Therapeutic compounds and methods of use | |
| IL287973A (en) | acss2 inhibitors and methods of their use | |
| IL279475A (en) | Actonucleotidase inhibitors and methods of using them | |
| ZA202400656B (en) | 6-aminopyrazolopyrimidine compound and pharmaceutical use thereof | |
| IL267344A (en) | Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy | |
| IL299245A (en) | LAIR-1 binding agents and methods of using them | |
| IL267503A (en) | Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy | |
| GB202306894D0 (en) | Therapeutic and prohylactic use of microoganisms | |
| IL264854A (en) | Spt5 inhibitors and methods of use thereof | |
| SG11202110545TA (en) | Inhibitors of notch signalling pathway and use thereof in treatment of cancers | |
| IL280453B1 (en) | History of benzenesulfonamide-phenyl-alkyloxy-alkyl acids and their use in therapy. | |
| ZA201903828B (en) | Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases | |
| IL299104A (en) | Intracellular administration of a CEBP antagonist and methods of use | |
| PL4153136T3 (pl) | Osmotyczne postacie dawkowania zawierające deutetrabenazynę i sposoby ich stosowania | |
| IL286149A (en) | Caspase inhibitors and methods of using them | |
| IL276792A (en) | Inhaler and methods for using it | |
| IL317235A (en) | Osmotic dosage forms comprising ditetrabenzene and methods of using the same | |
| HK40120984A (zh) | 包含氘代丁苯那嗪的渗透剂型及其使用方法 | |
| HK40123899A (en) | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |